Rx Medicare

The European Medicines Agency has recommended to the European Commission that two vaccines against influenza A(H1N1) (’swine flu’) be granted a marketing authorisation. Vaccines are one of the most important tools in the management of an influenza pandemic, helping to reduce illness and deaths by building up immune protection against the pandemic flu virus.

Read More…

Related Posts

• European Medicines Agency Updates On Pandemic Influenza
• European Medicines Agency Reaffirms Efficacy And Safety Of H1N1v Pandemic Vaccines
• CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In Children
• USDA Conducting Confirmatory Testing On Possible Detection Of 2009 Pandemic H1N1 Influenza In U.S. Swine
• Baxter Receives European Commission Approval For CELVAPAN H1N1 Pandemic Influenza Vaccine
• Diagnostic Hybrids Receives FDA Emergency Use Authorization For D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
• Statement By The Welsh Assembly Government On Latest Developments In Respect Of The Influenza A (H1N1) Swine Flu Pandemic
• Groups At High Risk Of H1N1 Influenza A Should Avoid Travelling To 2009 HAJJ
• FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
• Practice Fusion Identifies 300,000 High-Risk Patients For H1N1 Influenza Vaccine, In-line With CDC Pandemic Guidelines
• Cherokee County Death Linked To 2009 H1N1 Influenza
• Mobile Death Linked To 2009 H1N1 Influenza
• Fifteen Alabama Deaths Now Linked To 2009 H1N1 Influenza
• Three Additional Alabama Deaths Linked To 2009 H1N1 Influenza
• Baxter Receives EMEA Positive Opinion For CELVAPAN H1N1 Pandemic Influenza Vaccine

Tags: 2009, agency, authorisation, efficacy, european, h1n1, influenza, medicines, pandemic, recommends, vaccines

This entry was posted on Monday, September 28th, 2009 at 3:09 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.